Phreedom Pharma (PP) is the therapeutics division of Phenomenome Discoveries Inc. (PDI) that focuses on small molecule R&D. The areas of focus of PP are neurodegenerative diseases and oncology, based on breakthrough human metabolomics observations by PDI.
Complex metabolic imbalances are evident in both neurodegenerative diseases and in cancer. However, choosing appropriate metabolic targets for drug discovery programs is difficult and high risk. With the insights that have been obtained over the last 5 years by PDI in their metabolomics studies of defined human disease populations PP is poised to leverage a focused approach to drug R&D in these complex diseases. The R&D programs optimize mechanistic approaches to well defined targets that will correct critical metabolic imbalances in different multi-factorial diseases. In addition, the clinical biomarker assays developed by PDI will provide proprietary tools to assess efficacy in clinical trials of PP's drug candidates. The strategies that are currently being investigated are replacement therapies, in the case of a metabolic deficiency, and metabolic inactivation, in the case of metabolic excess.
This R&D process differs from traditional drug development in two key ways. First, it is biomarker-driven. PDI's biomarker discovery team first identifies a metabolic biomarker for a disease, and then the biochemistry of that biomarker drives the development of a therapeutic strategy. Historically, biomarker research has only been used to find markers of drug activity or response.
Second, our therapeutic strategy is to identify metabolic imbalances, and restore them, providing compounds that are part of natural biological function, thereby reducing the likelihood of side effects. In the case of replacement therapeutics, the strategy is to replace endogenous molecules in a patient's body rather than administer a foreign chemical.
In summary, PP has 3 major therapeutic programs as outlined in the following table:
| Mechanism | Dosing | Therapeutic Indication |
| Plasmalogen replacement | Oral | Alzheimer's Disease |
| Aldehyde sequestration | Oral | Multiple Sclerosis |
| γ-Tocotrienol analogs | Oral | Colorectal cancer |